Dana-Farber Cancer Institute, Boston, MA
Rachel A. Freedman , Ines Maria Vaz Duarte Luis , Nancy Lin , Joyce Lii , Eric P. Winer , Nancy Lynn Keating
Background: Few data are available about factors associated with completion of adjuvant trastuzumab in older women with BC. We examined rates and predictors of adjuvant trastuzumab completion for older women with early-stage BC. Methods: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify 1,319 patients ≥66 years with early-stage BC diagnosed between 1999-2007 who received trastuzumab. Completion of trastuzumab was defined as >270 days of therapy. We examined patient, clinical and geographic characteristics associated with trastuzumab completion using multivariable logistic regression. We also assessed rates of hospital admissions for cardiac events during treatment. Results: Most of the 1,319 women were aged ≤76 (70%) and had a comorbidity score=0 (88%); 37% and 23% received anthracyline-taxane-based and taxane-based therapy, respectively, and 16% received trastuzumab without chemotherapy. Overall, 982 women (74.5%) completed trastuzumab. Factors associated with completion are shown below. During treatment, 56 patients (4.2%) had 65 hospital admissions for cardiac events (3.0% in those who completed trastuzumab versus 8.0% in those who did not, p<.001). Conclusions: One-quarter of older patients who initiated adjuvant trastuzumab did not complete therapy. Older women, Hispanic women, those with more comorbidity, and those receiving anthracycline-taxane-based chemotherapy all had lower odds of completion. Rates of hosptializations for cardiac events were higher in those who did not complete therapy.
Adjusted odds ratio for completion (95% confidence interval) |
|
---|---|
Age 66-70 71-75 76-80 >80 |
-- 1.0 .8 (.6-1.1) .6 (.4-.8) .5(.4-.7) |
Race/ethnicity White Hispanic/other/unknown Non-Hispanic black |
-- 1.0 .7 (.5-.99) .8 (.5-1.3) |
Comorbidity 0 1 2+ |
-- 1.0 .1 (.3-.8) .3 (.2-1.5) |
Year of diagnosis ≤2005 >2005 |
-- 1.0 4.2 (2.5-6.9) |
Hormone receptor status Positive Negative |
-- 1.0 .8 (.7-1) |
Surgery Mastectomy Breast-conserving surgery No surgery/unknown |
-- 1.0 1.3 (1-1.6) 1.1 (.5-2.4) |
Chemotherapy Anthracycline/taxane Anthracycline based Taxane based Single taxane Other chemotherapy Other/no chemotherapy |
-- 1.0 1.2 (.8-1.8) 2.0 (1.6-2.6) 1.0 (.8-1.4) .6 (.3-1.2) 1.1 (.8-1.5) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Jenna Bhimani
2024 ASCO Quality Care Symposium
First Author: Erin Aiello Bowles
2023 ASCO Annual Meeting
First Author: Meghna S. Trivedi
2019 ASCO Annual Meeting
First Author: Young Chandler